ABT
Abbott Laboratories126.86
-1.61-1.25%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Nutrition pivot details guide trim
Q&A unpacked nutrition's drag on the 7% organic sales guide—0.5% below prior consensus—as price hikes crushed volumes, prompting swift promos and eight new launches with early encouraging signs despite H1 pain. Elsewhere, accelerations loom: diagnostics lapping China VBP/COVID, EP's Volt/Tactiflex Duo toolbox matching mid-teens market, CGM chasing another $1B low-teens gain via non-insulin coverage and ketone sensor. Pipeline executes flawlessly. Management dismissed MedTech volume fears, affirmed Exact Sciences close on track. Watch nutrition's six-month rebound.
Key Stats
Market Cap
220.79BP/E (TTM)
15.96Basic EPS (TTM)
7.95Dividend Yield
0.02%Recent Filings
8-K
Abbott closes Exact Sciences deal
Abbott completed its $105.00-per-share cash acquisition of Exact Sciences on March 23, 2026, making it a wholly owned subsidiary. This bolsters Abbott's cancer screening and diagnostics with Cologuard, Oncotype DX, and a $60 billion U.S. market foothold. Integration risks loom large. Exact Sciences delisted March 20.
8-K
Abbott issues $20B notes
Abbott Laboratories completed a $20 billion senior notes offering on March 9, 2026, with maturities from 2029 to 2066 and rates from floating to 5.600%. Proceeds will fund its pending Exact Sciences acquisition, repay target debt, and cover fees—yet trigger mandatory redemption at 101% if the deal fails by February 17, 2027. Deal risks loom large.
8-K
Abbott prices $20B notes
Abbott Laboratories priced $20 billion in senior notes on February 23, 2026, including floating-rate notes due 2029 and fixed-rate tranches maturing through 2066 at rates from 3.700% to 5.600%, with closing set for March 9. Proceeds will fund its acquisition of Exact Sciences Corporation, repay target debt, cover fees, and support general corporate purposes. Risks tie to acquisition uncertainties.
8-K
Board size reduced to 12
10-K
FY2025 results
Abbott's FY2025 sales hit $44.3B, up 5.7% y/y, driven by Medical Devices' 12.6% surge to $21.4B—Diabetes Care rocketed 17.5% to $8.0B—while Established Pharma grew 6.6% and Nutritionals held flat; Diagnostics dipped 4.3% on fading COVID tests. Operating margin swelled to 18.2% from margin tweaks, fueling $8.1B earnings. Q4 momentum roared in Devices, with double-digit gains across Heart Failure, Electrophysiology, and Rhythm Management. Cash swelled to $8.9B, funding $4.1B dividends (up 7.1%), $604M buybacks, and $2.2B capex; debt sits at $12.9B. Pending $21B Exact Sciences deal eyes cancer diagnostics. Supply chain snarls lurk.
ABBV
AbbVie Inc.
223.67-3.78
BDX
Becton, Dickinson and Company
196.39-3.70
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
BMRA
Biomerica, Inc.
2.37-0.08
BRKR
Bruker Corporation
44.96-0.71
BSX
Boston Scientific Corporation
92.95+0.76
CODX
Co-Diagnostics, Inc.
0.25-0.02
JNJ
Johnson & Johnson
209.30-4.87
MASI
Masimo Corporation
134.52-2.88
MDT
Medtronic plc.
97.72-0.85